Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mantry

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The New England Journal of Medicine|November 12, 2014
An interferon-free antiviral regimen for HCV after liver transplantationPaul Y Kwo, Parvez S Mantry, Eoin Coakley, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
Journal of Hepatology|October 7, 2018
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertibSaumya Jayakumar, Michael S Middleton, Eric J Lawitz, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The New England Journal of Medicine|November 12, 2014
An interferon-free antiviral regimen for HCV after liver transplantationPaul Y Kwo, Parvez S Mantry, Eoin Coakley, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
Journal of Hepatology|October 7, 2018
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertibSaumya Jayakumar, Michael S Middleton, Eric J Lawitz, et al.
Pageof 4